Our Executive Management Team focuses on the day-to-day operation of Salix Pharmaceuticals.
Thomas W. D'Alonzo
Acting Chief Executive Officer and Chairman of the Board
Thomas W. D'Alonzo has served as a member of our Board of Directors since May 2000 and has been the Chairman of the Board since June 2010. Mr D’Alonzo was named Acting Chief Executive Officer in February 2015. From March 2007 to February 2009, Mr D'Alonzo served as the Chief Executive Officer and a director of MiMedx Group, Inc. From May 2006 to April 2007, Mr D'Alonzo was Chief Executive Officer of DARA BioSciences, Inc, a pharmaceutical company, and he served on its Board of Directors from September 2005 to December 2008. From 2000 to 2007, Mr D'Alonzo acted as an independent consultant. Prior to that, from 1996 to 1999, Mr D'Alonzo served as President and Chief Operating Officer of Pharmaceutical Product Development (PPD), Inc, a global provider of discovery and development services to pharmaceutical and biotechnology companies. Before joining PPD, from 1993 to 1996, he served as President and Chief Executive Officer of GenVec, Inc, a clinical-stage biopharmaceutical company. From 1983 to 1993, Mr D'Alonzo held positions of increasing responsibility within Glaxo, Inc, the US division of GlaxoSmithKline plc, including President. Mr D'Alonzo received a BS in Business Administration from the University of Delaware and his J.D. from the University of Denver College of Law. Among other experience, qualifications, attributes and skills, Mr D'Alonzo's knowledge and experience in legal matters, in leading large organizations and serving on boards of directors in the life sciences industry led to the conclusion of our Nominating/Corporate Governance Committee and of our full Board that he should serve as a director of our Company in light of our business and structure.
William C. Bertrand, Jr.
Acting Chief Operating Officer
Mr. Bertrand joined Salix in July 2013 as Senior Vice President, General Counsel and Corporate Secretary, bringing more than 16 years of pharmaceutical experience and 24 years of legal experience. Mr Bertrand was named Acting Chief Operating Officer in February 2015. Prior to joining Salix, Mr. Bertrand spent 12 years at MedImmune, both prior to and after the acquisition by AstraZeneca, and at various times over his tenure had responsibility for legal, compliance, business development (including MedImmune Ventures, a wholly-owned venture fund), information technology, corporate affairs (internal and external communications), government relations and regulatory affairs. Before joining MedImmune, Mr. Bertrand held varying legal positions of increasing responsibility at Pharmacia & Upjohn, starting in product litigation and moving into global commercial and products support. Mr. Bertrand has also been a partner at a law firm, taught classes at Johns Hopkins University and Seton Hall University School of Law, and served on several boards of directors. Mr. Bertrand received his J.D. cum laude from the University of Wisconsin-Madison Law School and his B.S., high distinction, in Biology from Wayne State University.
William P. Forbes, PharmD
President, Medical, Research and Development, and Chief Development Officer
Dr Forbes joined Salix in January 2005 as Vice President, Research and Development, and Chief Development Officer, bringing more than 20 years of experience in pharmaceutical development. Dr Forbes was promoted to Senior Vice President in 2009 and to Executive Vice President, Medical, Research and Development, and Chief Development Officer in 2010. Currently he is President, Medical, Research and Development, and Chief Development Officer. Before joining Salix, Dr Forbes served as Vice President, Clinical Development and Regulatory Affairs, at Metabasis Therapeutics, Inc. Before that, he served as a Group Leader at Otsuka America Pharmaceutical, Inc, since 1996, and held various senior management positions in clinical research at Otsuka since 1991. Before joining Otsuka, Dr Forbes served as Senior Clinical Research Scientist at Glaxo, Inc. Dr Forbes has had responsibilities involving the clinical research and development of numerous new chemical entities in a variety of therapeutic indications, including gastroenterology and infectious disease. Dr Forbes received a PharmD from Creighton University and conducted postdoctoral work at the Creighton Cardiac Center and the Cardiovascular Clinical Research Department at Glaxo.
Timothy J. Creech
Senior Vice President, Finance and Administrative Services and Acting Chief Financial Officer
Mr. Creech who joined Salix in March 2007 as Executive Director, Finance, serves as Senior Vice President, Finance and Administrative Services and was appointed Acting Chief Financial Officer in November 2014. Mr. Creech has over 30 years of accounting and financial experience, including approximately 10 years at KPMG LLP and over 20 years in positions of significant responsibility at publicly traded companies. At Salix he previously served as Vice President, Finance and Administrative Services from May 2010 to March 2014, Associate Vice President, Finance from July 2008 to May 2010 and as Executive Director, Finance from March 2007 to July 2008. Prior to joining the Company, Mr. Creech served as Vice President, Finance at Voyager Pharmaceutical Corp. from 2004 to 2007, as Vice President, Finance, Principal Accounting Officer and Secretary at Trimeris, Inc. from 2002 to 2004, as Director of Finance at Trimeris from 1997 to 2002, as Corporate Controller at Performance Awareness Corporation from 1996 to 1997, as Director of Finance and Assistant Secretary at Avant! Corporation (formerly Integrated Silicon Systems) from 1993 to 1996 and at KPMG LLP from 1984 to 1993 in various positions of increasing responsibility progressing to Senior Manager. Mr. Creech received a BS in Business Administration from the University of North Carolina at Chapel Hill and a MBA from the Fuqua School of Business at Duke University.
Rick D. Scruggs
Executive Vice President, Business Development
Mr Scruggs joined Salix in 2000 as Director, National Accounts, bringing extensive experience in business development and commercial activities in the pharmaceutical industry. Mr Scruggs was promoted to Senior Vice President in 2009 and to Executive Vice President in 2011. Before joining Salix, Mr Scruggs served as Director of Managed Markets at Watson Pharmaceuticals, Inc, from May 1997 to July 2000. Prior to that, Mr Scruggs served as Director, Managed Markets and Trade, at Oclassen Pharmaceuticals, Inc, from January 1995 to February 1997. Before joining Oclassen, Mr Scruggs held various sales and marketing positions of increasing responsibility with Johnson & Johnson and Ciba-Geigy. Mr Scruggs received a BS in Criminal Justice from Appalachian State University.